Full Text View
Tabular View
No Study Results Posted
Related Studies
Amphetamine Cocaine Interaction Study - 2
This study has been terminated.
( P.I. left the institution )

First Received on September 20, 1999.   Last Updated on August 18, 2008   History of Changes
Sponsor: National Institute on Drug Abuse (NIDA)
Collaborator: University of Texas
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000305
  Purpose

The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Dextroamphetamine
Phase I

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Amphetamine Cocaine Interaction Study

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000305

Locations
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225
Sponsors and Collaborators
University of Texas
Investigators
Principal Investigator: John Grabowski, Ph.D. University of Texas
  More Information

No publications provided

Responsible Party: F. Gerard Moeller, M.D., University of Texas Medical School at Houston
ClinicalTrials.gov Identifier: NCT00000305     History of Changes
Other Study ID Numbers: NIDA-09262-2, P50-09262-2
Study First Received: September 20, 1999
Last Updated: August 18, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amphetamine
Methamphetamine
Dextroamphetamine
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on February 12, 2012